Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · Real-Time Price · USD

3.800

-0.030 (-0.78%)

Nov 3, 2026, 2:11 PM EST - Market open

Recursion Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	68.23	74.68	58.84	44.58	39.84	10.18
Revenue Growth	56.18%	26.92%	32.00%	11.88%	291.46%	156.89%
Gross Profit	-76.01	-471.54	-300.82	-239.24	-164.13	-125.09
Operating Income	-500.94	-648.13	-479	-350.06	-245.73	-182.78
Net Income	-475.67	-644.76	-463.66	-328.07	-239.48	-186.48
Earnings Per Share	-0.89	-1.44	-1.69	-1.58	-1.36	-1.49
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Research and Development Agreements	67.01	74.26	58.49	43.88	39.68	10
Grant	1.22	0.43	0.35	0.7	0.16	0.18
Revenue (Total)	68.23	74.68	58.84	44.58	39.84	10.18

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	549.85	743.29	594.35	391.57	549.91	516.56
Total Debt	74.7	77.97	108.49	50.67	51.01	0.72
Net Cash (Debt)	475.15	665.33	485.86	340.89	498.91	515.84
Net Cash Growth	-17.72%	36.94%	42.52%	-31.67%	-3.28%	106.63%
Net Cash Per Share	0.89	1.49	1.77	1.64	2.84	4.12

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-310.53	-371.81	-359.17	-287.78	-83.52	-158.61
Capital Expenditures	-1.95	-6.47	-13.7	-11.96	-37.06	-39.8
Free Cash Flow	-312.48	-378.28	-372.87	-299.74	-120.58	-198.41
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Margin	-734.17%	-867.87%	-814.09%	-785.33%	-616.74%	-1795.79%
Pretax Margin	-703.81%	-863.53%	-789.93%	-745.10%	-601.05%	-1832.18%
Profit Margin	-697.13%	-863.35%	-788.02%	-735.99%	-601.05%	-1832.18%
FCF Margin	-457.97%	-506.52%	-633.71%	-672.43%	-302.64%	-1949.42%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 3, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	33.91	28.50	45.32	47.92	36.68	284.42